OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $159,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock in a transaction dated Friday, November 22nd. The stock was acquired at an average price of $1.59 per share, with a total value of $159,000.00. Following the completion of the transaction, the chief executive officer now directly owns 211,712,405 shares of the company’s stock, valued at approximately $336,622,723.95. The trade was a 0.05 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Thursday, November 14th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Trading Up 1.3 %

OPK opened at $1.58 on Monday. The stock has a market capitalization of $1.08 billion, a PE ratio of -8.32 and a beta of 1.65. OPKO Health, Inc. has a one year low of $0.85 and a one year high of $1.75. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The business’s 50 day moving average price is $1.52 and its 200 day moving average price is $1.45.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Thursday, September 26th. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th.

Hedge Funds Weigh In On OPKO Health

Several large investors have recently modified their holdings of the business. CIBC Asset Management Inc raised its holdings in OPKO Health by 79.1% in the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 8,978 shares during the period. Hollencrest Capital Management raised its stake in shares of OPKO Health by 14.0% in the 2nd quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 11,020 shares during the period. FMR LLC lifted its holdings in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 11,089 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of OPKO Health by 4.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock worth $536,000 after purchasing an additional 17,671 shares during the period. Finally, Virtu Financial LLC acquired a new stake in OPKO Health in the 1st quarter valued at approximately $26,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.